Key result
Markedly elevated GDF-15 levels (>1800 ng/L) were associated with a 15.0% 3.6-year CHD mortality rate compared to 1.4% for normal levels (<1200 ng/L) in stable angina patients (P<0.001).
Why the study?
Does elevated GDF-15 predict CHD mortality in patients with stable and unstable coronary heart disease?
Population
2,229 patients with stable angina pectoris (n=1352) or acute coronary syndrome (n=877)
Comparison
Measurement of circulating… vs Comparison across GDF-15 strata: normal…
Design
Cohort
Follow-up
median 3.6 years
Authors
Loading...
GDF-15 may refine mortality risk stratification in stable angina beyond clinical models; leaves open whether testing improves outcomes or should guide therapy.
Cohort (n=2,229)
Does elevated GDF-15 predict CHD mortality in patients with stable and unstable coronary heart disease?
Absolute Event Rate: 15% vs 1.4%
p-value: p=<0.001
GDF-15 is a strong, independent predictor of CHD mortality across the spectrum of stable and unstable coronary heart disease, improving the prognostic accuracy of clinical risk models.
Kempf et al. (2009) conducted a cohort in Stable and unstable coronary heart disease (n=2,229). Growth-differentiation factor-15 (GDF-15) levels vs. Normal GDF-15 levels (<1200 ng/L) was evaluated on CHD mortality (p=<0.001). Markedly elevated GDF-15 levels (>1800 ng/L) were associated with a 15.0% 3.6-year CHD mortality rate compared to 1.4% for normal levels (<1200 ng/L) in stable angina patients (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: